While most thyroid ultrasound orders are warranted, researchers say guidelines could be clearer to help reduce over diagnosis of thyroid cancer.

A Rogel Cancer Center team created a guide to help providers navigate difficult conversations due to the coronavirus.

Cancer treatment research for glioblastoma enters new phase with FDA-approved drug trial that aims to improve the effect of radiation therapy on this aggressive brain cancer.

The multi-institution phase 1b/2a clinical trial found good tolerability and encouraging efficacy data for the pan-BET bromodomain inhibitor in combination with enzalutamide.

Multi-institution analysis identifies a new chromosomal abnormality linked to enzalutamide resistance.

While heat shock protein 90 inhibitors have shown limited benefit in directly treating cancer, low doses may improve the efficacy of radiotherapy, a new study finds.

Rather than attacking cancer cells directly, new cell-model research probes weaknesses in pancreatic cancer’s interactions with other cells to obtain nutrients needed for tumor growth.

New ovarian cancer research shows microRNA biomarker miR-181a could hold the key to earlier detection and treatment of the disease.

A U-M review found national Choosing Wisely recommendations to reduce overtreatment in early stage breast cancer weren’t consistently followed.

The protein Argonaute 2 was found to be critical to the progression from benign lesions into pancreatic cancer, suggesting a therapeutic opportunity.

The University of Michigan’s OncCOVID app draws on global cancer and coronavirus data to create an individualized mortality risk assessment for receiving immediate versus delayed cancer treatment.

A new precision medicine analytics tool called TransPRECISE developed to help oncologists with cancer treatment and research.

One program is helping people in the Arab-American community quit smoking for good during the month of Ramadan.

Transcriptional profiling identifies a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment.

Researchers have made strides toward targeting cancer in a new way. Through a collaboration between institutions and various scientific disciplines, scientists found a new way to attack a previously undruggable tumor suppressor.